 Opzeluras approval in vitiligo in the USA is the main growth driver. Next driver is Opzeluras approval for the vitiligo treatment in Europe. The issue with Jakafis LOE may be solved by the development of combo therapy and by the approval of a more comfortable frequency of usage. 